TBIQYR5005-Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2019

                                          
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.

The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.

Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.

North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.

Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. 


The global Drugs for Herpes Labialis (Oral Herpes) market is valued at 2040 million US$ in 2018 is expected to reach 3030 million US$ by the end of 2025, growing at a CAGR of 5.1% during 2019-2025.
This report focuses on Drugs for Herpes Labialis (Oral Herpes) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drugs for Herpes Labialis (Oral Herpes) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    GSK
    Novartis
    Teva
    Mylan
    Cadila
    Apotex
    Daewoong Pharmaceutical
    Livzon
    Luoxin
    Med shine
    Bayer (Campho Phenique)
    Blistex
    Kelun Group
    Hikma
    Haiwang
    Carmex
    Cipher

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Aciclovir
    Valacyclovir
    Famciclovir
    Docosanol
    Other

Segment by Application
    External Use
    Oral
    Injection